Neurodegenerative diseases like Alzheimer’s disease, Parkinson’s disease, dementia with Lewy bodies, age-related macular degeneration and Huntington’s disease involve different regions of the central nervous system yet they share key defects in cellular pathways. By selectively modulating a central cellular damage response pathway, Cognition’s drug candidates stop the toxic effects of age-related damage on brains cells that lead to neurodegeneration. By facilitating the normal function of this pathway, neurons in the brain and eye may function normally and avoid the effects of neurodegeneration.
A number of eye diseases, including dry AMD and geographic atrophy (GA), a more advanced form of the disease, are characterized by oxidative stress and an age-related buildup of toxic proteins that cause damage to retinal cells. CT1812 may remove these toxic proteins and restore downstream processes.
The age-related buildup of stressors such as oligomeric forms of proteins (Aβ, α-synuclein, huntingtin), reactive oxygen species and inflammatory agents drive many neurodegenerative diseases. We hypothesize that our our candidates have disease-modifying effects on a number of neurodegenerative and neuro-ophthalmic conditions.
Cognition’s biological discovery platform, through which CT1812 was identified, is based on unbiased phenotypic screens in the target cell population of mature primary neurons.
Cognition’s CEO, Lisa Ricciardi and CFO, James O’Brien plan to make a company presentation at the annual H.C. Wainwright Global Life Sciences Conference, being held virtually March 9-10, 2021.
Cognition publishes evidence that treatment with CT1812 improves disease-related biology in patients with Alzheimer’s disease in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association.
Cognition publishes findings identifying sigma-2 (σ-2) receptor as integral in Parkinson’s disease pathology
Pittsburgh, January 5, 2021 – Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways, today announced that President and CEO Lisa Ricciardi is participating in the Biotech Showcase™ 2021 conference and providing
